लोड हो रहा है...
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial
Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Cytokine release syndrome (CRS) is a CAR-T therapy–related adverse event. To date, clinical trials of different CAR-T products have not been align...
में बचाया:
| में प्रकाशित: | Blood Adv |
|---|---|
| मुख्य लेखकों: | , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
American Society of Hematology
2020
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7160283/ https://ncbi.nlm.nih.gov/pubmed/32271899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001304 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|